102 studies found for:    daclizumab
Show Display Options
Rank Status Study
1 Completed Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk
Condition: Renal Transplantation
Interventions: Drug: Thymoglobulin (ATG);   Drug: Daclizumab
2 Completed
Has Results
Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis
Conditions: Anterior Uveitis;   Arthritis, Juvenile Idiopathic;   Iritis;   Immunosuppression
Intervention: Drug: Daclizumab
3 Completed
Has Results
Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration
Conditions: Age-Related Macular Degeneration;   Choroidal Neovascularization
Interventions: Drug: Intravenous Daclizumab;   Drug: Intravenous Infliximab;   Other: Observation;   Drug: Oral Rapamycin
4 Recruiting Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin s Lymphoma
Conditions: Hodgkin Disease;   Hodgkin Lymphoma
Interventions: Radiation: 111In-daclizumab;   Radiation: 90Y-daclizumab
5 Completed
Has Results
Anti-Tac for Treatment of Leukemia
Conditions: HTLV-I Infection;   T Cell Leukemia
Intervention: Biological: daclizumab
6 Completed A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
Condition: Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
Intervention: Drug: Daclizumab
7 Active, not recruiting Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Biological: Daclizumab High Yield Process (DAC HYP) (Active);   Drug: Interferon beta-1a Placebo;   Biological: Interferon beta-1a (IFN β-1a) (Active);   Drug: Daclizumab High Yield Process Placebo
8 Completed Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)
9 Completed Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)
Condition: HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)
Intervention: Drug: CHOP-daclizumab
10 Completed Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis
Condition: Uveitis
Intervention: Drug: Daclizumab
11 Completed Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis
Condition: Uveitis
Intervention: Drug: Daclizumab
12 Completed To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris
Condition: Psoriasis
Interventions: Drug: Daclizumab;   Device: NB-UVB
13 Completed Daclizumab and Sirolimus to Treat Uveitis
Condition: Uveitis
Intervention: Drug: Daclizumab
14 Completed Combination Daclizumab/Denileukin Diftitox to Treat Uveitis
Condition: Non-Infectious Intermediate and Posterior Uveitis
Intervention: Drug: Daclizumab
15 Completed Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD
Condition: Graft vs Host Disease
Intervention: Drug: daclizumab, infliximab
16 Completed Safety and Efficacy Study of Daclizumab High Yield Process to Treat Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-remitting
Interventions: Biological: Daclizumab High Yield Process;   Other: placebo
17 Completed ANTI-TAC THERAPY FOR UVEITIS
Condition: Uveitis
Intervention: Drug: Daclizumab (Zenapax)
18 Completed MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Renal Transplant Patients
Condition: Kidney Transplantation
Intervention: Drug: daclizumab
19 Completed To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris
Condition: Psoriasis
Interventions: Drug: Daclizumab;   Drug: Cyclosporine;   Drug: cyclosporine and Daclizumab
20 Completed Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Subjects With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis.
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: Daclizumab High Yield Process 150 mg;   Biological: Daclizumab High Yield Process 300 mg

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years